Keyword: Rhythm Pharma

Fierce 15 winner Rhythm Pharmaceuticals is on the cusp of gaining its first approval in 2020, but will do so without its CEO.

Rhythm plans to complete a rolling submission to the FDA around the end of the year, positioning it to bring the drug to market in 2020.

Rhythm Pharma has additional data for its first-in-class obesity therapy setmelanotide showing that the drug’s effects can extend for over a year.

While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.

Flagship Pioneering has launched its latest biotech, Torque, as it hopes to power through using a new class of “deep-primed” immune cell therapies in cancer.

Rhythm Pharmaceuticals has topped its expectations in its IPO, selling more shares—at a higher price—than expected when it announced its intention to go public a few weeks back.

Rhythm Pharmaceuticals is looking to get off a beefy $115 million IPO as the biotech public offering window appears to be staying open.